Financial Performance Overview

Zydus Lifesciences Limited reported strong financial results for FY2025-26 with consolidated revenue growth of 17% to ₹271.5 billion and EBITDA margin of 31.2% (80 bps improvement). Net profit stood at ₹54.6 billion (15% YoY growth), while standalone performance showed net profit of ₹35.6 billion. The company maintained robust R&D investment at 8.4% of revenue (₹22.7 billion) and achieved ROCE of 21.6%.

Strategic Acquisitions and Expansion

The company completed several strategic acquisitions including Amplitude Surgical SA for entry into the MedTech space, Agenus biologics manufacturing facilities to establish biologics CDMO capabilities, and Comfort Click Limited to expand digital consumer healthcare. These acquisitions contributed significantly to revenue and expanded the company's global footprint across pharmaceuticals, medical devices, and biologics.

Research & Development Progress

Zydus advanced its clinical pipeline with Saroglitazar Magnesium filing NDA with USFDA for Primary Biliary Cholangitis treatment after completing EPICS-III Phase 2(b)/III trial. Usnoflast continued Phase 2(b) evaluation for Amyotrophic Lateral Sclerosis with Orphan Drug and Fast Track Designation. The company filed 142 patents and received 19 grants during the year, while launching biosimilars including Tishtha (Nivolumab) and Anyra (Aflibercept) in India.

Capital Allocation and Corporate Actions

The Board recommended a final dividend of ₹1 per share (100%) resulting in cash outflow of ₹1,006 million and approved a ₹11 billion share buyback program. The company maintained strong capital structure with authorized share capital of ₹1,725 million and paid-up capital of ₹1,006.23 million. Gross debt stood at ₹117.7 billion with debt-to-equity ratio of 0.43 times.

CSR and Sustainability Performance

Zydus reported CSR obligation of ₹548 million but spent only ₹101 million, transferring ₹447 million to unspent account due to delayed university project. Impact assessments showed significant benefits in healthcare access, education, and watershed development. ESG performance included 42% renewable energy mix, 11% reduction in energy intensity, and commitment to net water neutrality by 2028.

Corporate Governance and Compliance

The company maintained strong governance with 9 directors (5 independent, 2 women independent) and 7 Board committees. Compliance included penalty payments to BSE/NSE for regulatory non-compliance. The AGM is scheduled for August 11, 2026 with record dates established for dividend eligibility and e-voting.

Subsidiary Performance and Structure

The consolidated entity comprised 75 subsidiaries with material contributions from Zydus Healthcare Limited (23.18% of net assets), Zydus Wellness Limited (14.87%), and Zydus Pharmaceuticals USA Inc. (6.16%). Parent company Zydus Lifesciences Limited contributed 87.31% to net assets and 70.63% to profit.

Risk Management and Contingencies

The company disclosed contingent liabilities of ₹52.6 billion for corporate guarantees to subsidiaries and recognized exceptional items of ₹5.2 billion including one-time settlement cost of ₹4 billion and New Labour Code implementation impact. Foreign currency risk exposure showed 11% USD movement could impact PAT by ₹5.3 billion.

Outlook and Subsequent Events

Zydus signed definitive agreement to acquire Assertio Holdings for USD 166 million to strengthen US specialty oncology portfolio. The company continues to focus on strategic growth through organic expansion and targeted acquisitions while maintaining strong capital allocation discipline and governance standards.